24 slides from Arcticzymes Technologies Asa's earnings presentation, Feb 13, 2025
Slide 1: A Platform for Long-term Growth
February 13, 2025 A Platform for Long- CEO Michael Akoh CFO Børge Sørvoll term Growth VP Sales Paul Blackburn Q4 2024
Slide 2: Overview
Overview Overview AANorwegian Norwegianbiotech biotechwith with growth growth potential potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced considerable growth therapies and molecular Segment & Customers science t
Slide 3: Agenda
Agenda 1 Highlights Q4, Year in review and Priorities 2 Commercial Transformation 3 Sales - Biomanufacturing and Molecular Tools 4 Financials 5 Outlook and Q&A
Slide 4: Highlights Q4 2024
Highlights Q4 2024 Total Launch of New ERP system revenue New SAN HQ neo Go live 26.4 MNOK GMP December 2 (29.1 MNOK) EBITDA Launch of New commercial Performance New SensoPlus organization in 2.7 MNOK ELISA kit place (1.9 MNOK) Building a Platform for Long-term Growth
Slide 5: 2024 - Year in Review
2024 - Year in Review A Year of Transition & Strategic Progress to Position for Growth Commercial Transformation Strengthened leadership with new VP Sales, Marketing Director and Business Development Managers to accelerate revenue growth Strategic Partnerships Partnership with leading viral vector C
Slide 6: Strategic priorities
Strategic priorities Building a platform for long term growth – the journey has started Short Term Long Term Build Advanced therapies biomanufacturing pipeline to 1 Customer centric Transformation 1 broaden and diversify portfolio Commercialization – strengthen commercial arm significantly RNA enzym
Slide 7: New solutions to complete the GMP portfolio
New solutions to complete the GMP portfolio One step further towards a complete suite of unique GMP nucleases Two new products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo The new SAN HQ GMP neo is a GMP-compliant version of ArcticZymes' SAN HQ Triton FREE Proactively addressing the increasingly strin
Slide 8: Commercial transformation
Commercial transformation 8
Slide 9: Building Commercial Strength
Building Commercial Strength Paul Blackburn – VP Sales and Marketing What Why Positioning Why I’m drives me ArcticZymes for the future excited …using my experience to build ArcticZymes represents the perfect We are in a strong position to scale, This is a pivotal moment. The high-performing teams, d
Slide 10: Enhancing Our Approach
Enhancing Our Approach From Product Focus to Customer Partnership 2025 State sformation n Tra What w e will achieve State rent oint r gp Cu Startin CURRENT APPROACH EVOLVED APPROACH Strong product expertise, focus on features & price Deeper customer insight, understanding workflows and challenges Re
Slide 11: Evolving Commercial Processes and Culture
Evolving Commercial Processes and Culture Default to “Yes" Customer First Mindset Center all activities around Foster a proactive, positive customer needs to strengthen approach to customer requests relationships Encourage Listen Possibilities & Adapt Accelerate decision-making and Move Solve with e
Slide 12: …what customers are saying
…what customers are saying Having SAN in our production process has boosted our confidence in meeting stringent regulatory requirements. - A major European CDMO When we first saw the results with SAN, it was almost too good to be true. The DNA degradation and purity levels Ok, hang oour expectations
Slide 13: Sales Update Q4 2024
Sales Update Q4 2024
Slide 14: Q4 Sales — Overview
Q4 Sales — Overview Biomanufacturing and Molecular Tools ✓ Quarterly sales of 24.4 MNOK — reflecting recalibration from 28.4 MNOK in Q4 2023 as order dynamics shift ✓ Stronger customer engagement: +7.5% more customers and +9.6% more orders — signaling growth in market reach ✓ First time since 2021 t
Slide 15: Q4 Sales — Biomanufacturing
Q4 Sales — Biomanufacturing Steady Performance with Expanding Customer Base ✓ Q sales steady at 12.2 MNOK (vs. 12.3 MNOK Q4 2023) — reflecting a strong market presence despite headwinds ✓ Biomanufacturing accounts for 50% of total Q4 sales — highlighting its strategic importance ✓ Customer base cont
Slide 16: Q4 Sales — Molecular Tools
Q4 Sales — Molecular Tools Strengthening Customer Diversification ✓ Q sales at 12.2 MNOK (vs. 16.1 MNOK in Q4 2023) — reflecting shifting customer demand patterns ✓ Molecular Tools accounted for 50% of Q4 sales — underscoring its continued importance in the portfolio ✓ Lower demand from a few large
Slide 17: 2024 – Growing Customer Base, Navigating Market Shifts
2024 – Growing Customer Base, Navigating Market Shifts Unique customers up vs. 2023, with biomanufacturing traction balancing Molecular Tools shifts Unique customers reached their highest level in recent years, driven by biomanufacturing growth and market expansion. Biomanufacturing Orders stable, A
Slide 18: Expenses & Profitability
Expenses & Profitability
Slide 19: ERP system - LIVE
ERP system - LIVE To support scalability and compliance Major project completed with a GO live date December 2th Will improve efficiency and productivity down the road Validated software in compliance with ISO13485 regulation Traceability through the value chain Data security Internal control A tool
Slide 20: Profitability and expenses
Profitability and expenses Expense development continues according to plan Q4 YTD 2024 2023 2024 2023 Sales revenues 24,5 28,4 104,4 118,9 Other revenues 1,9 0,7 3,8 0,7 Sum revenues 26,4 29,1 108,2 119,7 Cost of materials -1,7 -1,8 -8,9 -11,7 Change in inventory 0,2 -0,3 3,0 5,8 Personnel expenses
Slide 21: ERP impacted results in Q4
ERP impacted results in Q4 Project Complete Q4 2024 2023 Sales revenues 24,5 28,4 Other revenues 1,9 0,7 • Q4 2024 impacted negatively by MNOK 1.5 in Sum revenues 26,4 29,1 ERP implementation. Cost of materials -1,7 -1,8 • Scrapping of raw materials Q4 2023 of MNOK Change in inventory 0,2 -0,3 0,5 P
Slide 22: Cash flow and short-term investments
Cash flow and short-term investments +1.8 MNOK in changes for Q4* Cash and STI position 280 30 Short term investments (STI) Net Cash (MNOK) 25 260 Changes in Cash and STI (MNOK) 20 240 Changes in cash and STI (MNOK) 15 Net Cash (MNOK) 220 10 5 200 0 180 -5 160 -10 140 -15 Q1 2023 Q2 2023 Q3 2023 Q4
Slide 23: Outlook 2025
Outlook 2025 Commercial transformation: • New commercial team in place • More resources across organization engaged in customer facing activities SAN OEM partnership: • Discussions with a number of partners on an OEM agreement on SAN CDMO platform partnership: • Platform implementation during Q2 of
Slide 24: Thank you Q&A
Thank you Q&A arcticzymes.com